Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

Bubbles are mechanisms of wealth redistribution and destruction - with detrimental consequences for social and geopolitical ...

Explore new findings on bipolar disorder, from genetics to sleep patterns, plus emerging treatments and a neuroscientist’s ...